Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 73.7% in January

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 1,434 shares, a decrease of 73.7% from the January 15th total of 5,444 shares. Based on an average trading volume of 25,027 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s stock are sold short. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 25,027 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Several research firms recently weighed in on BRNS. HC Wainwright lifted their price target on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $4.00.

Barinthus Biotherapeutics Stock Performance

BRNS stock opened at $0.71 on Wednesday. The firm has a 50 day moving average price of $0.72 and a 200-day moving average price of $1.02. Barinthus Biotherapeutics has a 52-week low of $0.64 and a 52-week high of $2.92. The firm has a market capitalization of $28.99 million, a price-to-earnings ratio of -0.38 and a beta of -0.66.

Institutional Investors Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. raised its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 192,461 shares of the company’s stock after acquiring an additional 100,000 shares during the period. Baird Financial Group Inc. owned approximately 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.